Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases — Stella

Home/Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

View on ClinicalTrials.gov

Recruiting

Back to Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

Tianjin Medical University General Hospital

Enrollment target

~27 participants

Started

April 2025

Primary completion

December 2027

Age range

18 Years – 60 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.